Arctic Vision Ltd.

Arctic Vision Ltd. is a China-based ophthalmic biotech startup, founded in 2019, with a focus on breakthrough therapies in the field. The company's slogan "Dual-Engine Powered Innovation Pioneer in Ophthalmology" reflects its commitment to leveraging cutting-edge technology and consumer-oriented approaches to bring meaningful and game-changing innovations in ophthalmology. Arctic Vision's last investment of $100.00M in Series B at 09 March 2021 attracted significant attention from prominent investors such as Morningside Ventures, Loyal Valley Capital, Nan Fung Life Sciences, Octagon Capital Advisors, Pivotal bioVenture Partners China, Tencent, and Adrian Cheng, indicating strong support and confidence in the company's potential in the industry. The company's dedication to understanding end-user insights and unlocking ophthalmic innovations is supported by its elite team of ophthalmic industry veterans, with proven track records in research, development, and commercialization of eye care products. Additionally, Arctic Vision is backed by recognized life science investors and biotechnology venture capital with broad networks in China, Asia, the United States, and Europe, providing the company with valuable industry knowledge and experience in business incubation. Arctic Vision's aspirations to access the Chinese market and drive long-term strategic clinical development and growth position it as a trusted partner for global biopharmaceutical companies. The company's dual-engine growth strategy, as well as its commitment to pushing the boundaries of exploration and innovation, demonstrates its dedication to improving vision for mankind and bringing about positive change. In summary, Arctic Vision is well-positioned in the biotechnology and healthcare industries, particularly within the ophthalmic sector. With significant investments and strong industry connections, the company showcases great promise in delivering impactful ophthalmic innovations globally.